CIBC Asset Management Inc Raises Position in Natera, Inc. (NASDAQ:NTRA)

CIBC Asset Management Inc grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,663 shares of the medical research company’s stock after purchasing an additional 186 shares during the period. CIBC Asset Management Inc’s holdings in Natera were worth $580,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Finally, True Wealth Design LLC purchased a new position in Natera in the 3rd quarter worth $57,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $162.31 on Friday. Natera, Inc. has a 52 week low of $69.74 and a 52 week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.43 billion, a PE ratio of -92.22 and a beta of 1.66. The stock’s 50-day moving average price is $167.98 and its 200-day moving average price is $145.54.

Insider Activity

In other news, insider John Fesko sold 663 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the sale, the chief financial officer now owns 70,629 shares in the company, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock worth $49,741,699 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NTRA. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.